For research and educational purposes only. Not medical advice.

BPC-157 Reference

Educational, not medical advice reference for BPC-157: Recovery; regulatory status, evidence posture, source review, and schedule notes. Also kn…

Reference summary

Published literature is dominated by preclinical rodent injury-healing work spanning tendon, ligament, muscle, gastrointestinal mucosa, vascular, and central-nervous-system models. Mechanistic work points to VEGFR2 activation and the Akt-eNOS nitric oxide pathway driving angiogenesis, fibroblast migration, and neuromuscular stabilization, particularly in poorly vascularized tissues such as tendons and myotendinous junctions. Direct human evidence remains extremely limited. The original Pliva-sponsored Phase 2 program of PL 14736 enema for mild-to-moderate ulcerative colitis was completed but never published in a peer-reviewed journal, and only a small number of pilot reports exist in humans. A 2025 narrative review in Current Reviews in Musculoskeletal Medicine concluded that BPC-157 should still be considered investigational and used with caution until well-designed human trials are conducted.

Regulatory and posture

Categories
Recovery
Aliases
BPC 157, Body Protection Compound-157, Pentadecapeptide BPC-157, Stable gastric pentadecapeptide BPC 157, PL 14736, PL-10, PLD-116
Evidence posture
preclinical - Mostly animal data. Pliva Phase 2 ulcerative-colitis program (PL 14736) was abandoned and never published; only a handful of small human pilot reports exist.
Regulatory status
No FDA-approved drug label for human use. On September 29, 2023, FDA placed BPC-157 (acetate and arginate salt forms) in Category 2 of the 503A interim bulk drug substances list, meaning FDA identified significant safety concerns and BPC-157 is not permitted for use in section 503A pharmacy compounding; BPC-157 was not among the five peptides removed from Category 2 in September 2024. Prohibited at all times (in-competition and out-of-competition) under WADA S0 non-approved substances. No therapeutic use exemption is available because BPC-157 is not approved for human therapeutic use in any country.
Content review status
research reference

Selected public sources

Related tools